An observational study in Brain Tumor, Primary, Meningioma and Schwannoma, sponsored by Seoul National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.
Sponsored by Seoul National University Hospital · Observational
Among 11 studies in Pituitary Neoplasms with a site in Korea, Republic of — 1 open to participants now, 1 under way, none of them phase 3. Pituitary Neoplasms · Korea, Republic of.
Among the 11 studies in Pituitary Neoplasms with a site in Korea, Republic of, this one is the only one that started in 2001, is one of 3 observational ones, and was the 11th registered.
200 studies on the registry are indexed under Pituitary Neoplasms; 51 are open to participants now.
Browse Pituitary Neoplasms studies →1 of the 11 studies in Pituitary Neoplasms with a site in Korea, Republic of is open now.
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 36 Pituitary Neoplasms studies recruiting now, 14 (39%) set no upper age limit and 10 (28%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 163 across 74 observational studies indexed under Pituitary Neoplasms.
Median enrollment 75 across the 8 interventional studies, 1,600 across the 3 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 7 most frequent:
Seoul National University Hospital is the lead sponsor of 1,900 studies on the registry; 274 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Seoul National University Hospital has 4 studies filed under Pituitary Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Pituitary Neoplasms with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. In all MRs taken by patients, the date of imaging and the volume of the tumor are measured, and we aim to establish a natural growth history for non-malignant brain tumors.
Non-malignant central nervous system (CNS) tumor accounts for 70% of all primary CNS tumors, and over 300,000 patients were diagnosed with non-malignant CNS tumor per year in the United States. Not much is known about the natural history of non-malignant CNS tumors, as it is often treated immediately upon detection. However, some of them, especially small and asymptomatic non-malignant CNS tumors should not be treated immediately upon diagnosis but are observed and followed-up by repeated magnetic resonance imaging (MRI). This study aims to make a prospective cohort of non-malignant CNS tumors that do not require immediate treatment and to quantitatively analyze which factors are related to the growth of tumors.
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had MR re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed neoplasms of CNS WHO grade 2 or lower among primary intracranial tumors and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant.
200 studies on the registry are indexed under Pituitary Neoplasms; 51 are open to participants now.
This study's planned enrollment of 3,000 is above the median of 163 across 74 observational studies indexed under Pituitary Neoplasms.
Browse Pituitary Neoplasms studies →Seoul National University Hospital is the lead sponsor of 1,900 studies on the registry; 274 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Compared within Pituitary Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Brain Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Investigators defined the cohort population as adults with radiologically diagnosed non-malignant brain tumor that do not require immediate treatment who agree to participate.
Inclusion Criteria for retrospective cohort
Inclusion Criteria for prospective cohort
Exclusion Criteria
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 1998, and who have had MR re-examination after first MR exam because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed primary intracranial neoplasms of CNS WHO grade 2 or lower and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant. It is practically impossible to obtain informed consent from patients of this retrospective cohort, and consent was waived by the Institutional Review Board. Target population of this retrospective cohort is 1,500 tumors.
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since February 2022, and who have had MR re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed primary intracranial neoplasms of CNS WHO grade 2 or lower and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant. The cohort will consists of patients who agree to participate with written consent. Target population of this prospective cohort is 1,500 tumors.
Tumor volume in each MRI
Measured tumor volume in each MRI
Time frame: within 15 years after enrollment
T2 signal intensity of tumor in each MRI
T2 signal intensity of tumor as a ratio to contralateral white matter
Time frame: within 15 years after enrollment
Growth rate of tumor volume between MR exams (absolute volume)
Tumor volume changed on average per year
Time frame: within 15 years after enrollment
Growth rate of tumor volume between MR exams (volume ratio)
Percentage of tumors that change on average per year
Time frame: within 15 years after enrollment
Number of patients who eventually received treatment
Number of patients who eventually received treatment, such as surgery, radiosurgery, radiotherapy, or hormonal therapy.
Time frame: within 15 years after enrollment
Pre-treatment follow-up period for patients who eventually received treatment
Pre-treatment follow-up period for patients who eventually received treatment, such as surgery, radiosurgery, radiotherapy, or hormonal therapy.
Time frame: within 15 years after enrollment
Plan to share: No — We have no plan to share our individual participant data because is is not permitted by the Institutional Review Board.
Started Jan 2001 (actual). Primary completion is estimated for Dec 2035, 419 months after the start.
Of 33 observational studies under Pituitary Neoplasms, half reached primary completion within 163 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 349. This study's planned 419 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →